Valve Medical celebrates a momentous achievement as they announce the successful implantation of their ultra-low profile transcatheter aortic valve replacement (TAVR) valve in Israel.

Thursday, June 01, 2023

Valve Medical, a wholly owned subsidiary of Medinol Ltd., is thrilled to announce a momentous achievement. Today, they successfully performed the First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel. This groundbreaking procedure introduces a revolutionary advancement in Structural Heart procedures, as it incorporates the world's first modular valve. Valve Medical's remarkable accomplishment highlights their dedication to pushing the boundaries of medical innovation and improving patient care.

Valve Medical is introducing the Xemed TAVR device, an innovative technology aimed at improving patient outcomes and procedural success. The standout feature of this valve is its modular design, which offers an ultra-low profile, allowing for the use of a standard 12 Fr sheath. This reduction in size enables universal access to trans-femoral delivery, even for patients with smaller arteries, while minimizing the risk of complications such as vascular issues and bleeding that are common in traditional TAVR procedures.

One of the key advantages of the Xemed TAVR device is its simplified vessel closure at the end of the procedure, resulting in reduced procedure times and a lighter workload for physicians and support staff. Additionally, the device incorporates multiple technical advancements, including an adaptive sealing technology that helps reduce paravalvular leakage, a common complication associated with TAVR procedures.

Prof. Ran Kornowski, the implanting physician at Rabin Medical Center, expressed their positive experience with the device, stating, "We were impressed with the device and its straightforward implantation. The low profile will allow us to treat a broader population of patients by making the procedure safer and more accessible.

Dr. Yoram Richter, founder and Chief Scientific Officer of Valve Medical, emphasized the device's versatility, stating, "We believe that the ultra-low profile,adaptive sealing, ease of coronary access, and advanced frame shape expand the device's applicability, providing clinical benefits for both patients and physicians. Valve Medical is also proud to announce their ongoing efforts to further reduce the device's profile to an impressive 9 Fr, demonstrating their commitment to continuous improvement and innovation.

Aortic stenosis, a common valvular disease affecting millions globally, can be effectively addressed through TAVR, a minimally invasive procedure that replaces a damaged aortic valve without open-heart surgery. TAVR is particularly beneficial for patients who are not eligible for traditional surgical interventions.



Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit